Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center.
Beckman Research Institute.
Curr Opin Oncol. 2020 Sep;32(5):518-526. doi: 10.1097/CCO.0000000000000662.
This article focuses on the immunosuppressive impact of myeloid-derived suppressor cells (MDSCs) and the potential clinical implications in hematological malignancies.
MDSCs play a critical role in the regulation of the immune response in cancer. They inhibit activation of adaptive immune response and as a result foster the growth of the malignancy. Recent studies have shown that MDSCs serve as prognostic biomarkers and as targets for cancer immunotherapy. Preclinical and clinical studies have identified new approaches to deplete MDSC populations and inhibit MDSC function with combination immunomodulatory therapies including chemotherapeutic agents with immune checkpoint-directed treatment.
A broad spectrum of publications indicate that direct targeting of MDSCs may abrogate their protumorigenic impact within the tumor microenvironment through activation of the adaptive immune response.
本文重点介绍髓系来源抑制细胞（MDSCs）的免疫抑制作用及其在血液恶性肿瘤中的潜在临床意义。
MDSCs 在癌症免疫反应的调控中起着关键作用。它们抑制适应性免疫反应的激活，从而促进恶性肿瘤的生长。最近的研究表明，MDSCs 可作为预后生物标志物，并可作为癌症免疫治疗的靶点。临床前和临床研究已经确定了新的方法来消耗 MDSC 群体，并通过联合免疫调节治疗抑制 MDSC 功能，包括化疗药物与免疫检查点靶向治疗。
大量文献表明，通过激活适应性免疫反应，直接针对 MDSC 可能会消除其在肿瘤微环境中的促肿瘤作用。
